The Current Ratio as of November 2024 (TTM) for Cellectis S.A. (CLLS) is 1.78

According to Cellectis S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 1.78. This represents a change of 4.19% compared to the average of 1.71 of the last 4 quarters.

Cellectis S.A. (CLLS) Historical Current Ratio (quarterly & annually)

How has CLLS Current Ratio performed in the past?

The mean historical Current Ratio of Cellectis S.A. over the last ten years is 5.02. The current 1.78 Current Ratio has changed 3.44% with respect to the historical average. Over the past ten years (40 quarters), CLLS's Current Ratio was at its highest in in the June 2018 quarter at 12.49. The Current Ratio was at its lowest in in the December 2023 quarter at 1.50.

Cellectis S.A. (CLLS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cellectis S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cellectis S.A. (CLLS) Average Current Ratio

How has CLLS Current Ratio performed in the past?

The current Current Ratio of Cellectis S.A. (CLLS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cellectis S.A. (CLLS) Current Ratio vs. Peers

How is CLLS’s Current Ratio compared to its peers?

Cellectis S.A.’s Current Ratio is less than Sigilon Therapeutics, Inc. (2.40), less than DiaMedica Therapeutics Inc. (11.81), less than NeuBase Therapeutics, Inc. (2.87), less than Soleno Therapeutics, Inc. (17.26), less than Genfit S.A. (3.74), less than Cyteir Therapeutics, Inc. (21.89), less than ERYTECH Pharma S.A. (3.65), less than Eliem Therapeutics, Inc. (60.41), greater than HCW Biologics Inc. (0.07), less than Innate Pharma S.A. (2.92), less than Inhibrx Biosciences, Inc. (4.70), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Crinetics Pharmaceuticals, Inc. (16.38), less than Passage Bio, Inc. (5.15), less than REGENXBIO Inc. (3.05), less than LianBio (10.06), less than Kezar Life Sciences, Inc. (7.65), less than Foghorn Therapeutics Inc. (4.77), less than Shattuck Labs, Inc. (7.96), less than Monte Rosa Therapeutics, Inc. (6.03), less than Kymera Therapeutics, Inc. (8.55), less than Nurix Therapeutics, Inc. (5.28),

Build a custom stock screener for Cellectis S.A. (CLLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cellectis S.A. (CLLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.